Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06818474 · ClinicalTrials.gov registry record · Phase 4
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
A Phase 4 study of Angioedema, sponsored by Bernstein Clinical Research Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06818474 is a Phase 4 study of Angioedema that is actively recruiting participants, run by Bernstein Clinical Research Center. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06818474, a Phase 4 study of Angioedema, is actively recruiting participants, sponsored by Bernstein Clinical Research Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
use of lanadelumab in patients with acquired angioedema
Conditions Studied
Interventions
- BIOLOGICAL Lanadelumab 300 mg
Study Locations (1)
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06818474
The ClinicalTrials.gov registry entry for NCT06818474 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bernstein Clinical Research Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Angioedema appearing as the primary indexed condition, and to 1 intervention - of which Lanadelumab 300 mg is the first listed.
NCT06818474 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06818474 about?
NCT06818474 is a clinical study titled "Lanadelumab in Long-term Prophylaxis of Acquired Angioedema". use of lanadelumab in patients with acquired angioedema
What is the current status of trial NCT06818474?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2024-06-01. Estimated completion is 2027-12-01.
What conditions does trial NCT06818474 study?
This clinical trial studies the following conditions: Angioedema.
What interventions are being tested in trial NCT06818474?
The interventions under investigation include: Lanadelumab 300 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT06818474?
This trial is sponsored by Bernstein Clinical Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06818474 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.